Symposium: Shortwave Presenting Clinical Research
Summary by AI BETAClose X
SHORTWAVE LIFE SCIENCES PLC
("Shortwave" or "the Company")
2 December 2025
PSYCH Symposium London 2025: Shortwave Life Sciences to Present Emerging Clinical Research as Gold Partner
Shortwave Life Sciences plc announces that it will serve as a Gold Partner at the PSYCH Symposium, taking place on 4 December 2025 at Conway Hall, London. The Symposium is recognised as one of the leading international forums for scientific and clinical discussion on psychedelic-based treatments. It brings together senior clinicians, neuroscientists, policy specialists, research institutions and programme leaders from Europe and North America to examine emerging data, regulatory developments and future pathways for patient access.
As part of the official programme, Dr Nadya Lisovoder, Chief Medical Advisor at Shortwave Life Sciences, will deliver a session titled Designing Breakthroughs: A New Human Study for Anorexia Treatment. Her presentation will outline the rationale for Shortwave's feasibility study exploring psychedelic-assisted therapy for severe anorexia nervosa. This will include current understanding of neural circuit dysfunction, rigid cognitive patterns and anxiety-driven reward systems associated with chronic anorexia, as well as early findings from Shortwave's psilocybin based buccal film programme, which is designed to support controlled delivery and improved tolerability in medically fragile patient groups.
Following her presentation, Dr Lisovoder will join Kate Spicer of The Sunday Times for a conversation focused on the clinical and regulatory barriers that have limited innovation in anorexia treatment and the implications of new research for patients and families.
Dr Lisovoder commented: "PSYCH Symposium brings together the leading clinical and scientific figures shaping the development of psychedelic-based treatments. Anorexia nervosa remains one of the most lethal psychiatric conditions, and there is an ongoing need for treatments grounded in strong science. Our research aims to understand the mechanisms that may support change in a condition defined by chronic relapse and limited therapeutic options. Presenting this work at PSYCH allows us to engage with colleagues who are generating important evidence across multiple therapeutic areas."
Shortwave's decision to support the Symposium reflects the Company's focus on research that advances rigorous clinical understanding and informs future regulatory assessment. The event convenes investigators working on programmes in depression, post-traumatic stress, alcohol use disorder, end-of-life anxiety and treatment-resistant conditions, making it a central forum for organisations advancing next-generation mental health treatments.
"Our participation as a Gold Partner at PSYCH Symposium places Shortwave within a group of organisations that are setting the pace for the next phase of psychedelic medicine. The Symposium offers an important platform to present our clinical direction and to strengthen relationships with researchers, clinicians and policymakers who are central to the development in this field. This represents a significant step in the progression of our scientific programme." added Rolf Gerritsen, Director of Shortwave Life Sciences.
A drinks reception hosted by Shortwave Life Sciences will take place immediately following the close of the Symposium on 4 December, providing an opportunity to meet attending researchers, clinicians and partners.
About Shortwave Life Sciences:
Shortwave Life Sciences is a developer of breakthrough therapies addressing unmet medical needs in mental health. The Company is committed to the advancement of innovative solutions through drug development, with a mission to pioneer breakthrough therapies that transform the landscape of mental health care. With a team of dedicated experts and a commitment to innovation, Shortwave Life Sciences is uniquely positioned to introduce and develop solutions for the complex challenges of mental health disorders worldwide.
The Directors of the Company accept responsibility for the contents of this announcement.
For media inquiries, please contact:
Enquiries:
Company:
Rolf Gerritsen
+44 20383 87621
AlbR Capital Limited:
Corporate Adviser:
+ 44 (0) 20 7469 0930
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund